CCL18 Exhibits a Regulatory Role through Inhibition of Receptor and Glycosaminoglycan Binding

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Krohn, Sonja C ^a   Bonvin, Pauline ^a,b   Proudfoot, Amanda E I ^a  

^a MERCK SERONO S A   (Switzerland)

^b NovImmune   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR5; GLYCOSAMINOGLYCAN; MONOCYTE CHEMOTACTIC PROTEIN 2;

ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL CHEMOTAXIS; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BINDING, COMPETITIVE; CARBOCYANINES; CELLS, CULTURED; CHEMOKINES; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; GLYCOSAMINOGLYCANS; HUMANS; KINETICS; PROTEIN BINDING; RECEPTORS, CCR; RECEPTORS, CCR3; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84881503494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072321     Document Type: Article

References (44)

1. Zlotnik A, Yoshie O, (2000) Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127. doi:10.1016/S1074-7613(00)80165-X. PubMed: 10714678.
2. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, et al. (2002) Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 22: 1067-1068. doi:10.1089/107999002760624305. PubMed: 12433287.
3. Johnson Z, Proudfoot AE, Handel TM, (2005) Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 16: 625-636. doi:10.1016/j.cytogfr.2005.04.006. PubMed: 15990353.
4. Rot A, (1992) Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today 13: 291-294. doi:10.1016/0167-5699(92)90039-A. PubMed: 1510812.
5. Proudfoot AEI, Handel TM, Johnson Z, Lau EK, LiWang P, et al. (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 100: 1885-1890. doi:10.1073/pnas.0334864100. PubMed: 12571364.
6. Burns JM, Gallo RC, DeVico AL, Lewis GK, (1998) A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. J Exp Med 188: 1917-1927. doi:10.1084/jem.188.10.1917. PubMed: 9815269.
7. Ali S, Hardy LA, Kirby JA, (2003) Transplant immunobiology: a crucial role for heparan sulfate glycosaminoglycans? Transplantation 75: 1773-1782. doi:10.1097/01.TP.0000065805.97974.93. PubMed: 12811234.
8. Hieshima K, Imai T, Baba M, Shoudai K, Ishizuka K, et al. (1997) A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 159: 1140-1149. PubMed: 9233607.
9. Wells TN, Peitsch MC, (1997) The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases. J Leukoc Biol 61: 545-550. PubMed: 9129202.
10. Li H, Ruben S, Macrophage inflammatory protein-3 and-4. United States Patent Patent Number: 5,504,003. United States patent application.
11. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, et al. (1997) A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387: 713-717. doi:10.1038/42716. PubMed: 9192897.
12. Kodelja V, Müller C, Politz O, Hakij N, Orfanos CE, et al. (1998) Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 160: 1411-1418. PubMed: 9570561.
13. Schraufstatter I, Takamori H, Sikora L, Sriramarao P, Discipio RG, (2004) Eosinophils and monocytes produce pulmonary and activation-regulated chemokine, which activates cultured monocytes/macrophages. Am J Physiol Lung Cell Mol Physiol 286: L494-L501. doi:10.1152/ajplung.00323.2002. PubMed: 12716654.
14. Guan P, Burghes AH, Cunningham A, Lira P, Brissette WH, et al. (1999) Genomic organization and biological characterization of the novel human CC chemokine DC-CK-1/PARC/MIP-4/SCYA18. Genomics 56: 296-302. doi:10.1006/geno.1998.5635. PubMed: 10087196.
15. de Nadaï P, Charbonnier AS, Chenivesse C, Sénéchal S, Fournier C, et al. (2006) Involvement of CCL18 in allergic asthma. J Immunol 176: 6286-6293. PubMed: 16670340.
16. Günther C, Bello-Fernandez C, Kopp T, Kund J, Carballido-Perrig N, et al. (2005) CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 174: 1723-1728. PubMed: 15661937.
17. Chenivesse C, Chang Y, Azzaoui I, Ait YS, Morales O, et al. (2012) Pulmonary CCL18 recruits human regulatory T cells. J Immunol 189: 128-137. doi:10.4049/jimmunol.1003616. PubMed: 22649201.
18. Lindhout E, Vissers JL, Hartgers FC, Huijbens RJ, Scharenborg NM, et al. (2001) The dendritic cell-specific CC-chemokine DC-CK1 is expressed by germinal center dendritic cells and attracts CD38-negative mantle zone B lymphocytes. J Immunol 166: 3284-3289. PubMed: 11207283.
19. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, et al. (2002) Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 277: 24584-24593. doi:10.1074/jbc.M112275200. PubMed: 11978786.
20. Vulcano M, Struyf S, Scapini P, Cassatella M, Bernasconi S, et al. (2003) Unique regulation of CCL18 production by maturing dendritic cells. J Immunol 170: 3843-3849. PubMed: 12646652.
21. Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, et al. (2003) Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 29: 743-749. doi:10.1165/rcmb.2003-0078OC. PubMed: 12805086.
22. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, et al. (2006) A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173: 781-792. doi:10.1164/rccm.200509-1518OC. PubMed: 16415274.
23. Schraufstatter IU, Zhao M, Khaldoyanidi SK, Discipio RG, (2012) The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology 135: 287-298. doi:10.1111/j.1365-2567.2011.03541.x. PubMed: 22117697.
24. Chang Y, de Nadai P, Azzaoui I, Morales O, Delhem N, et al. (2010) The chemokine CCL18 generates adaptive regulatory T cells from memory CD4+ T cells of healthy but not allergic subjects. FASEB J 24: 5063-5072. doi:10.1096/fj.10-162560. PubMed: 20702776.
25. Schutyser E, Richmond A, Van Damme J, (2005) Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 78: 14-26. doi:10.1189/jlb.1204712. PubMed: 15784687.
26. Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, et al. (2003) PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 163: 2065-2075. doi:10.1016/S0002-9440(10)63564-X. PubMed: 14578205.
27. Nibbs RJ, Salcedo TW, Campbell JD, Yao XT, Li Y, et al. (2000) C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap. J Immunol 164: 1488-1497. PubMed: 10640766.
28. Catusse J, Wollner S, Leick M, Schröttner P, Schraufstätter I, et al. (2010) Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol 225: 792-800. doi:10.1002/jcp.22284. PubMed: 20568229.
29. Chen J, Yao Y, Gong C, Yu F, Su S, et al. (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19: 541-555. doi:10.1016/j.ccr.2011.02.006. PubMed: 21481794.
30. Proudfoot AE, Borlat F, (2000) Purification of recombinant chemokines from E. coli. Methods Mol Biol 138: 75-87. PubMed: 10840744.
31. Severin IC, Souza AL, Davis JH, Musolino N, Mack M, et al. (2012) Properties of 7ND-CCL2 are modulated upon fusion to Fc. Protein Eng Des Sel 25: 213-222. doi:10.1093/protein/gzs008. PubMed: 22388887.
32. Severin IC, Gaudry JP, Johnson Z, Kungl A, Jansma A, et al. (2010) Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J Biol Chem 285: 17713-17724. doi:10.1074/jbc.M109.082552. PubMed: 20363748.
33. Krohn S, Garin A, Gabay C, Proudfoot AEI, (2013) The activity of CCL18 is principally mediated through interaction with glycosaminoglycans. Frontiers in Immunology/ Chemoattractants in press.
34. Arunlakshana O, Schild HO, (1959) Some quantitative uses of drug antagonists. PMC1481829: 48-58.
35. Schild HO, (1949) pAx and competitive drug antagonism. Br J Pharmacol 4: 277-280. PubMed: 18141089.
36. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, et al. (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38: 12959-12968. doi:10.1021/bi990711d. PubMed: 10504268.
37. Schutyser E, Struyf S, Wuyts A, Put W, Geboes K, et al. (2001) Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis. Eur J Immunol 31: 3755-3762. doi:10.1002/1521-4141(200112)31:12. PubMed: 11745396.
38. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, et al. (2001) The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 276: 2986-2991. doi:10.1074/jbc.M005652200. PubMed: 11110785.
39. Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M, (2001) Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 97: 1920-1924. doi:10.1182/blood.V97.7.1920. PubMed: 11264152.
40. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, et al. (1999) CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94: 1899-1905. PubMed: 10477718.
41. Kenakin P, (1900) A Pharmacology Primer-orthosteric drug antagonism. In: A Pharmacology Primer, 3 edition: theory, applications and methods.
42. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, et al. (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59: 707-715. PubMed: 11259614.
43. Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, et al. (2001) The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 276: 10620-10626. doi:10.1074/jbc.M010867200. PubMed: 11116158.
44. Graham GJ, Wilkinson PC, Nibbs RJ, Lowe S, Kolset SO, et al. (1996) Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP-1alpha by mutagenesis of the proteoglycan binding site. EMBO J 15: 6506-6515. PubMed: 8978677.